Previous 10 | Next 10 |
- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020 ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close. The consensus EPS Estimate is $0.11 (+237.5% Y/Y) and the consensus Revenue Estimate is $33.19M Over the last 2 years, cprx has beaten EPS estimates 50...
ADPT , ADT , BREW , CBPX , CDLX , CPRX , DDOG , DOX , HALO , HCAT , HIIQ , HTHT , HUYA , KWR , MCRN , MTSI , OMER , PTE , RUN , SDC , SENS , SSTI , SWKS , TLRY , TVTY , TWOU , VRAY , VREX , YY For Seeking Alpha's full earnings season calendar, click here . ...
Yesterday, Catalyst Pharmaceuticals (NASDAQ: CPRX) announced that its flagship drug, Firdapse (amifampridine phosphate), failed to meet the primary endpoint of a late-stage trial as a treatment for congenital myasthenic syndrome, a genetically based muscle disorder that can lead to a person ...
CORAL GABLES, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
A 20-subject Phase 3 clinical trial, CMS-001 , evaluating Catalyst Pharmaceuticals' (NASDAQ: CPRX ) Firdapse (amifampridine phosphate) in patients at least two years old with symptomatic genetically confirmed congenital myasthenic syndromes (CMS), a group of conditions characterized by mu...
CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints MuSK-Myast...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Investing in small-cap stocks isn't for the faint of heart. This asset classes has historically shown higher volatility than the broader market. However, picking the right small-cap stock -- and watching it appreciate in value over time -- can pay rich dividends down the road. It isn't easy to ...
Catalyst Pharmaceuticals ( CPRX -3.1% ) is trimming losses after the disclosure of an insider purchase from its CEO and president. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...